Results 171 to 180 of about 182,947 (342)

Tryptophan Metabolite Indole‐3‐Aldehyde Induces AhR and c‐MYC Degradation to Promote Tumor Immunogenicity

Advanced Science, EarlyView.
Tryptophan metabolite Indole‐3‐aldehyde (I3A) downregulates cytosolic AhR and p‐ERK/c‐MYC proteins, together enhancing STAT3 phosphorylation and tumor immunogenicity. Overexpression of the Trp metabolic enzyme interleukin‐4‐induced gene‐1 (IL4I1) in tumor cells increases intracellular levels of I3A and enhances tumor immunogenicity.
Lei Cui, Zining Wang, Zixuan Guo, Hongxia Zhang, Yongxiang Liu, Huanling Zhang, Huan Jin, Feifei Xu, Xiaojuan Wang, Chunyuan Xie, Hui Guo, Tiantian Wang, Yanxun Lin, Qi Zhao, Penghui Zhou, Jing Tan, Jin‐Xin Bei, Peng Huang, Jinyun Liu, Xiaojun Xia   +19 more
wiley   +1 more source

Synthetic growth hormone-releasing hormone agonist ameliorates the myocardial pathophysiology characteristic of heart failure with preserved ejection fraction. [PDF]

Cardiovasc Res, 2023
Dulce RA, Kanashiro-Takeuchi RM, Takeuchi LM, Salerno AG, Wanschel ACBA, Kulandavelu S, Balkan W, Zuttion MSSR, Cai R, Schally AV, Hare JM.   +10 more
europepmc   +1 more source

Growth Hormone Releasing Factor Activity in the Stalk-Median Eminence and Plasma Growth Hormone Response to the Ether-Laparotomy Stress in the Rat

, 1974
Norio Ogawa
openalex   +2 more sources

XBP1s Mediates Cross‐resistance to Combination Treatment of CDK4/6 Inhibitors plus Endocrine Therapy in Breast Cancer

Advanced Science, EarlyView.
Elevated spliced form of X‐box–binding protein 1 (XBP1) correlates with unfavorable responses to endocrine therapy plus CDK4/6 inhibitors in HR+/HER2− advanced breast cancer. XBP1s facilitates cell proliferation and G1/S transition by transcriptionally activating SND1, thereby activating the E2F1 pathway.
Yuting Sang, Shiyang Liu, Xujie Zhou, Weiru Chi, Min Xiong, Ming Chen, Hengyu Ren, Douwaner Liu, Liyi Zhang, Jingyan Xue, Yayun Chi, Jiong Wu   +11 more
wiley   +1 more source

Growth Hormone-Releasing Hormone in Endothelial Inflammation.

Endocrinology, 2022
Barabutis N, Akhter MS, Kubra KT, Jackson K.   +3 more
europepmc   +1 more source

Tumorigenic transformation of human prostatic epithelial cell line RWPE-1 by growth hormone-releasing hormone (GHRH). [PDF]

Prostate, 2022
Muñoz-Moreno L, Carmena MJ, Prieto JC, Schally AV, Bajo AM.   +4 more
europepmc   +1 more source

LRRC8A Regulates Outer Hair Cell Volume and Electromotility and is Required for Hearing

Advanced Science, EarlyView.
This study identifies LRRC8A‐dependent volume‐regulated anion channels (VRACs) as essential for cochlear outer hair cells' electromotility and auditory signal amplification. LRRC8A deficiency disrupts cell volume control, impairs auditory sensitivity, and causes deafness, while targeted LRRC8A re‐expression restores auditory function.
Shengnan Wang, Yuehui Xi, Qiaojun Fang, Sai Shi, Fei Wang, Fuyu Xian, Zhongyang Zhang, Yuxin Yang, Xishuo Jin, Xiaomin Wang, Chen Cao, Hailin Zhang, Nikita Gamper, Zhigang Xu, Haitao Shen, Ping Lv   +15 more
wiley   +1 more source

Growth hormone - releasing hormone in the immune system. [PDF]

Rev Endocr Metab Disord
Siejka A, Lawnicka H, Fakir S, Barabutis N.   +3 more
europepmc   +1 more source

Growth Hormone-Releasing Hormone Antagonist JV-1-36 Suppresses Reactive Oxygen Species Generation in A549 Lung Cancer Cells. [PDF]

Endocrines, 2022
Kubra KT, Akhter MS, Apperley K, Barabutis N.   +3 more
europepmc   +1 more source

Isolation, primary structure, and synthesis of human hypothalamic somatocrinin: growth hormone-releasing factor. [PDF]

, 1984
N Ling, Frederick Esch, Peter Böhlen, Paul Brazeau, W B Wehrenberg, Roger Guillemin   +5 more
openalex   +1 more source